publications and presentations

Presentations

Synergistic Protective Effect of Antibodies Against Polysaccharide Type 3 and Pneumococcal Proteins in a Highly Virulent Type 3 Invasive Disease Model in Mice
T. Stevenson, S. Roggensack, H. Burke, P. Ghosh, S. Sebastian, Y.J. Lu, F. Zhang, R. Malley, G. Besin
Presented at: 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12), June 19-23, 2022, Toronto, Canada.

Immunogenicity and Efficacy of a Multiple Antigen-presenting System (MAPS™) COVID-19 Vaccine in Non-human Primates
Gilles Besin, Brian Cieslewicz, Daniel Makrinos, Renuka Haridas, Heidi Burke, Taylor Stevenson, and Richard Malley. 2022. Immunogenicity and efficacy of a multiple antigen-presenting system (MAPS™) COVID-19 vaccine in Non-human Primates. Presented at: IMMUNOLOGY 2022™, Annual Meeting of The American Association of Immunologists, May 6-10, The American Association of Immunologists, Inc., Portland, OR, Abstract 2760.

Safety and Immunogenicity of ASP3772, a Novel 24-Valent Pneumococcal Vaccine, in Older Adults
Gurunadh R Chichili, Ronald Smulders, Vicki Santos, Beth Cywin, Laura Kovanda , Charles Van Sant, Frank Malinoski, Shite Sebastian, George Siber, Richard Malley. Oral presentation of Phase 2 results at European Congress of Clinical Microbiology & Infectious Diseases (July 2021)

Safety and Immunogenicity of a Novel 24-Valent Pneumococcal Vaccine in Healthy Adults
Gurunadh R. Chichili, Ronald Smulders, Vicki Santos, Beth Cywin, Laura Kovanda, Frank Malinoski, Shite Sebastian, George Siber, Richard Malley. Poster presentation of Phase 1 results at ID Week 2020 (October 2020)

 

Publications

Gurunadh R. Chichili, Ronald Smulders, Vicki Santos, Beth Cywin, Laura Kovanda, Charles Van Sant, Frank Malinoski, Shite Sebastian, George Siber, Richard Malley, Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years, Vaccine, Volume 40, Issue 31, 2022, Pages 4190-4198, ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2022.05.079.

Zhang F, Lu YJ, & Malley R (2013) Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci USA 110(33):13564-13569.

van Sorge NM, Cole JN, Kuipers K, Anna Henningham A, Ramy K. Aziz RK, Kasirer-Friede A, Lin L, Berends ETM, Davies MR, Dougan G, Zhang F, Dahesh S, Shaw L, Gin J, Cunningham M, Merriman JA, Hütter J, Lepenies B, Rooijakkers SHM, Malley R, Walker MJ, Shattil SJ, Schlievert PM, Choudhury B, Nizet V. The Classical Lancefield Antigen of Group A Streptococcus is a Virulence Determinant with Implications for Vaccine Design. (2014) Cell Host & Microbe (15) 729-740

Zhang F, Lu YJ, Sharp J, Broering T, Bodmer V, Sharma O, Tavangar K, Ledue O, and Malley R. Design and evaluation of a multiple antigen presenting system (MAPS)-based pneumococcal vaccine to prevent invasive disease and carriage. 10,th International Symposium on Pneumococci & Pneumococcal Diseases, Glasgow, UK, May 26th, 2016

Zhang F, Ledue O, Jun M, Goulart C, Malley R, Lu YJ. (2018) Protection against Staphylococcus aureus colonization and infection by B- and T-cell-mediated mechanisms. mBio 9:e01949-18. https://doi.org/10.1128/mBio.01949-18.

A. Cross, T. Broering, R. Simon, F. Michon, R. Malley, S. Tennant, J. Sinclair, M. Leney, M. Amin, J. McCombs, R. Wallacott, G. Saia, D. Molrine, G. Siber, D. Ambrosino. Novel Multivalent Vaccine for Gram-Negative Bacterial Pathogens, including Multiple Antibiotic-resistant Strains. World Vaccine Congress, April 14-17, 2019. Washington DC.

Back to Top
 

This links to an external website.

Continue